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Abstract 
In spite of the unquestionable positive impact of HAART in the treatment of HIV infection, the discovery 
and development of novel agents directed towards other targets of the replicative cycle of the virus that 
differ from those targeted by the clinically approved drugs, emerges nowadays as an imperative need. The 
blockade of HIV entry is a highly promising strategy against the pathogen and glycoprotein gp120 is a 
central actor in this process. This review discusses the current status in the research of anti-HIV agents 
targeting specifically the envelope protein gp120. The diverse approaches devoted to the achievement of 
therapeutic agents against gp120 currently under study are organized and analyzed critically according to 
their specific mechanism of inhibition and structural features. 
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1. Introduction 
Acquired immunodeficiency syndrome (AIDS) is one of the most devastating infectious diseases 
in the history of mankind. Entering the fourth decade of the AIDS pandemic after the first official cases 
reported in 1981, it is calculated that more than 34 million people were living worldwide at the end of 
2011 infected by the human immunodeficiency virus (HIV), the causative agent of the disease, and a 
higher number is expected in the future. Only in 2011, more than 2.5 million people became newly 
infected and the number of deceases from AIDS-related causes worldwide during the same year reached 
the dramatic figure of 1.7 million people [1]. Due to its increasing extension and the high associated 
mortality rate, there is no doubt that AIDS represents a global health threat and that fighting this disease 
remains one of the major challenges for chemotherapy in the 21
st
 century. 
HIV is a unique and formidable pathogen. Actually, besides rapidly mutating to evade the immune 
system, HIV targets the cells needed to fight infection. By infecting helper T cells (specifically CD4
+
 T), 
macrophages, dendritic and glial cells, which are all central regulators of the immune response, HIV 
causes a frame of severe immunodeficiency resulting in high susceptibility to opportunistic pathogens, 
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thus superimposing HIV with other endemic or epidemic infections. This is a daunting challenge because 
in most cases the association between these infections worsens both diagnoses.  
In spite of the continued expansion of the HIV around the globe, it appears that the number of 
people infected has been stabilized over the last few years. This is a consequence of the efforts made for 
the development of efficient treatments against HIV and of their spread to a larger infected population. 
Unfortunately, despite recent developments [2], the search for a vaccine for this devastating epidemic 
disease still remains as an elusive task. Furthermore, it has not been possible to develop effective 
microbicides to prevent the transmission of HIV [3]. However, although there is no treatment currently 
that fully eradicates HIV-1 infection, to date there has been 26 clinically approved drugs directed against 
four different viral targets (three enzyme systems involved in key steps of the replicative cycle (i.e. 
reverse transcriptase, protease and integrase) and the viral envelope protein gp41) and one cellular target 
(CCR5 co-receptor) (Table 1) [4]. Therefore, thanks to the chemotherapeutic arsenal available to date, 
AIDS has been converted from a fatal illness into a chronic disease in an impressively short time, barely 
20 years [5], which represents a huge achievement which can hardly be parallel in the whole history of 
medicine as a result of concerted multidisciplinary work. 
Contemporary therapy against HIV-1 is based on the so-called Highly Active Anti-Retroviral 
Therapy (HAART) that consists of the treatment with a combination of three or more complementary 
drugs which are directed against critical stages of the infectious cycle of the virus [6]. While this strategy 
has contributed to the slow down or even the suppression of viral replication and ultimately the 
progression of AIDS, strongly improving the survival of the infected patients, HAART does not manage 
to fully eradicate the persistence of long-term reservoirs of HIV [7]. Moreover, frequent adverse effects 
and drug resistance are important drawbacks after prolonged treatment [8] [9]. It should be emphasized 
also that HAART is highly focused on a narrow number of therapeutic targets in the HIV cycle (Reverse 
Transcriptase (RT) and Protease (PR), see Table 1). Despite the unquestionable success of the antiviral 
treatment based in drugs directed against RT and PR, the replicative cycle of HIV presents several 
potential targets for therapeutic actuation that have to be exploited. 
As a result of all that is mentioned above, intensive efforts in the discovery of effective drugs to 
treat HIV must continue. Therefore, the research on novel antiretroviral drugs directed to new molecular 
targets in the machinery of the HIV replicative cycle or the development of compounds directed to known 
and validated targets but exerting their inhibitory effect through new mechanisms that differ from those 
employed by the clinically in-use drugs results a priority area of maximum interest in the field of HIV 
chemotherapy [10]. Particularly, a great interest has arisen in the development of anti-HIV agents directed 
towards the blockage of intrinsic viral components rather than cellular elements as this strategy would 
avoid the disruption of the normal function of the host cell causing toxic or side effects. In this context, a 
new class of anti-HIV drugs have emerged very recently directed towards the inhibition of the viral entry 
process.  
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Family of compounds Drug 
Reverse Transcriptase Inhibitors  
Nucleosides 
(NRTIs) 
 
Zidovudine (AZT, 1987) 
Didanosine (ddI, 1991) 
Zalcitabine (ddC, 1992) 
Stavudine (d4T, 1994) 
 
Lamivudine (3TC, 1995) 
Abacavir (ABC, 1998) 
Emtricitabine (FTC, 2003) 
 
Nucleotides 
(NRTIs) 
 
 
Tenofovir (TNV, 2001) 
 
Non-nucleoside 
(NNRTIs) 
 
Nevirapine (NVP, 1996) 
Delavirdine (DLV, 1997) 
Efavirenz (EFV, 1998) 
Etravirine (ETR, 2008) 
Rilpivirine (RPV, 2011) 
 
Protease Inhibitors  
(PIs) 
 
 
Saquinavir (SQV, 1995) 
Indinavir (IDV, 1996) 
Ritonavir (RTV, 1996) 
Nelfinavir (NFV, 1997) 
Amprenavir (APV, 1999) 
 
 
Lopinavir (LPV, 2000) 
Atazanavir (AZV, 2003) 
Fosamprenavir (FPV, 2003)  
Tipranavir (TPV, 2005) 
Darunavir (DRV, 2006) 
 
 
Integrase Inhibitors 
(IIs) 
 
 
Raltegravir (RTV, 2007) 
 
Entry/Fusión 
Inhibitors 
Gp41 Inhibitors 
 
Enfuvirtide (ENV, 2003) 
 
CCR5 Antagonists 
 
Maraviroc (MRV, 2007) 
 
 
Table 1. Drugs approved to date as HIV inhibitors for clinical use classified according to their target [4] (In 
brackets, the usual acronym of the drug and the date of approval by the FDA). 
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The HIV-1 cell entry is a complex multistage process subtly regulated (see section 2.2). This 
process is mediated by the HIV-1 env glycoproteins gp120 and gp41, located at the surface of HIV-1 and 
highlighted as promising targets for drug discovery. Two recently approved drugs endorse this point. 
Enfuvirtide [11] targets the envelope viral gp41 protein, and Maraviroc [12] acts as a cellular CCR5-
binding antagonist, both preventing HIV-1 from adequately entering the host cell at the early steps of the 
infection. Moreover, these compounds have been demonstrated to be active against virus strains which 
were resistant to the previous classes of anti-HIV-1 agents used in HAART [13]. Consequently, both 
drugs Enfuvirtide and Maraviroc would constitute a proof-of-concept that proves viral entry as a critical 
step susceptible to inhibition at different levels, providing researchers with diverse therapeutic targets 
validated and effectives for the treatment of the HIV-1 infection.  
The development of antiviral agents that target glycoprotein gp120 represents a particularly major 
challenge because it can be considered the very first point of contact between the host cell and the 
pathogen. Moreover, there is to date no clinically approved drugs directed towards gp120 in spite of the 
intensive efforts carried out in the research and development of gp120 inhibitors over the last years. For 
these reasons, this review will be focused in the different strategies targeting specifically gp120 reported 
to date, compiling and updating the original approaches followed in this field. Additionally, novel 
strategies directed to inhibit gp120 that have not been previously summarized (i.e., CBA approach) will 
be included in this critical review. Although excellent highlights and monographs have been published 
covering the overall entry inhibitors from diverse perspectives [14], there are almost no focused overviews 
about compounds that specifically inhibit gp120-cell receptors interactions and this overview endeavors 
to fill this void [15]. 
 
2. HIV entry process 
2.1. Viral components of HIV-1 entry: gp120 structure and function 
The mature human immunodeficiency virus HIV-1 consists roughly in two copies of a single-
stranded RNA that codify the genes of the virus. These RNAs, together with a series of critical viral 
enzyme systems (Reverse Transcriptase (RT), Ribonuclease (RB), Integrase (IN) and Protease (PR)) are 
all surrounded by a conical peptidic capside. This viral nucleocapside is enclosed in a spherical lipidic 
envelope bilayer derived from the host cell membrane upon budding. Several virus-encoded envelope 
glycoproteins (env proteins) are embedded on the outer membrane, asymmetrically distributed over the 
external surface of the HIV-1 displayed like “spikes”. Each envelope glycoprotein complex is formed by 
a heterodimer resulting from the non-covalent association of two proteins called gp41 and gp120. 
Glycoprotein gp41 adopts a transmembrane location, anchored to the viral membrane and behaving as 
physical support of gp120, the latter being fully located on the external surface of the HIV-1 membrane. 
Both gp41 and gp120 are homotrimeric proteins synthesized from a common single chain polypeptide 
precursor gp160, which eventually is cleaved post-transductionally yielding the mature independent env 
proteins.  
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The structure of the glycoprotein gp120 has been determined using X-ray techniques by the 
crystallization of several complexes of gp120 with CD4, human antibodies or drugs [16]. Very recently it 
has been possible to obtain highly-resolved crystal structures of unliganded core gp120 from different 
HIV-1 clades [17]. Notably, all the reported bound and unbound structures resemble a common CD4-
bound-like state. Each gp120 monomer unit is composed of five hypervariable regions (V1-V5) and five 
highly conserved regions (C1-C5). It has been elucidated that gp120 is constituted by a central core 
consisting in two main domains: an inner and an outer domain (Figure 1). The inner domain is mainly 
composed by conserved regions and directly interacts with gp41; while the outer domain is mostly 
comprised by variable regions which are heavily glycosylated and form five variable loops by the 
establishment of inter-chain disulfide bonds that make up the most exterior portion of the gp120 
ectodomain. The main function of these variable loops is to protect the conserved domains and to evade 
the immunological response from the host cell. Additionally, some sections of the variable domains have 
an extra important role such as V3 that is involved in the binding of gp120 to the cellular chemokine co-
receptors (CCR5 and/or CXCR4). Both domains are slightly spatially separated in unliganded gp120 and 
come together when the viral glycoprotein gp120 attaches to the primary cellular CD4 receptor, which 
induces conformational changes that results in the formation of a third domain termed the bridging sheet. 
This domain is constituted by two pairs of anti-parallel β-sheets and plays an important role in the 
subsequent interaction with cellular chemokine co-receptors.  
A highly remarkable feature of the HIV-1 envelope glycoprotein gp120 is the presence of a large 
carbohydrate component (glycan) accounting for approximately 50% of its overall molecular weight. It 
has been stated that these carbohydrates are bound to the peptide part of gp120 by a variable number of 
N-glycosylation sites (between 18 and 33) through asparagine residues belonging to Asn-X-Ser/Thr 
motifs (where X is any amino acid except proline) distributed profusely along the gp120 surface [18]. 
Despite the genetic variation among different isolates and clades of HIV-1, N-glycosylation sites are 
spatially conserved giving place to a dense glycan coating that surrounds the outer surfaces of the protein 
[19].  
The glycans located at the surface of the gp120 glycoprotein are synthesized originally by the 
host cells using their own glycosylation machinery and incorporated subsequently by the pathogen 
[20]. The structural nature of these surface carbohydrates is quite variable, consisting in a diverse array of 
different oligosaccharides. However, in spite of the common biosynthetic origin, a few unique features in 
the pattern of gp120 glycosylation emerge entirely as a result of the viral modulation of the host 
glycosylation pathways and allow distinguishing gp120 glycans from those of the host membrane 
glycoproteins. Thus, these carbohydrates have been determined to be composed derived from a common 
structural motif based in a pentasaccharide core formed by two N-acetylglucosamine and three mannose 
subunits (Man3GlcNAc2, Figure 2) linked at the appropriate N-glycosilation sites on the polypeptide 
chain of gp120. This pentasaccharide core is functionalized like most of the glycoproteins of the host, 
producing hybrid, complex-type glycans and an unusual high level of oligomannoses (known as high-
mannose) that consist in the pentasaccharide core functionalized additionally with up to 9 residues of 
mannose [21]. Such a high density of high-mannose type glycans has never been observed on mammalian 
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glycoproteins [22]. On the other hand, as previously mentioned, viral glycans form a dense, intricate and 
homogeneous coating spatially distributed on the surface of gp120, forming additionally tight clusters by 
glycan-glycan interaction that efficiently mask the peptide backbone of the protein. This is again a 
distinctive feature, unique and peculiar of gp120 because prokaryotic cells rarely express proteins 
carrying this type of dense glycans.  
 
  
(a) (b) 
  
(c) 
Figure 1. Structures of unliganded HIV-1 envelope glycoprotein gp120 (from HIV-1 clade B strain, YU2) 
[17] (a) molecular surface structures of homotrimer; (b) ribbon diagram of homotrimer; (c) detailed crystal 
structure gp120 core displayed as ribbon diagram. Outer domain is highlighted in green, inner domain in 
orange and bridging sheet in blue. The variable domains (V1-V5) are indicated by red arrows. Figures were 
edited and adapted from the deposited pdb data 3TGQ (DOI 10.2210/pdb3tgq/pdb). Figures were generated 
by Pymol program.  
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The role of the gp120 glycans is critical in the infectious process as they help in the entry process 
into susceptible target cells and in the efficient transmission of the pathogen. Moreover, these 
oligosaccharides are crucial in avoiding an efficient neutralizing antibody response against HIV-1 in 
infected people. This is as a consequence of several factors. First, the virus has low antigenicity because 
the critical immunogenic epitopes located on the peptide surface of gp120 are hidden by the exceptional 
density of glycan array and are not easily accessible for antibody binding [23]. Secondly, the virus has a 
low immunogenicity because the carbohydrates surrounding the envelope spikes of gp120 only stimulate 
a weak antibody response. Finally, the high mutational rate of the HIV-1 virus induces continued 
variations and renewal of the carbohydrates of the surface preventing antibody recognition but not CD4 
receptor binding. This mechanism has been developed by HIV-1 to escape immunological neutralization 
contributing to a high viral persistence in the face of an evolving antibody repertoire. The viral strategy 
has been intuitively described as an “evolving glycan shield” and amplifies the antigenic effect of 
relatively small sequence changes to the Asn-X-Ser/Thr-X motif [24]. 
 
 
 
Figure 2. Structure of the common pentasaccharide core of N-linked glycans in gp120. Brown arrows indicate 
positions for further functionalization of the core.   
 
The gp120 glycans have also been suggested to play an important role in viral transmission 
through interaction with endogenous lectins able to selectively recognize specific glycan motifs in HIV-1, 
such as the C-type lectin DC-SIGN, which is found on the surfaces of dendritic cells and is thought to aid 
in the transport of the virus to anatomical sites rich in CD4
+
 T cells (i.e., lymphatic nodes) [25]. 
Glycoprotein gp120 serves as the first point of contact with the host cell and plays a central role in 
the entry process mediating in the attachment to CD4 and further co-receptor binding. However, once 
these steps have been completed, the ultimate phase of the entry of HIV into the host cell, independently 
recognized as the fusion step, involves the glycoprotein gp41. Besides anchoring the gp120 subunit to the 
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viral membrane, gp41 eventually directs the fusion of viral and host cell membranes, triggering the entry 
of the HIV capsid inside the cell [26]. 
The gp41 subunit of the env proteins has also been studied in great detail [27]. Like gp120, it exists 
as a homotrimer. Structurally, it comprises of three clearly differentiated domains, a large extracellular 
part (ectodomain), a transmembrane spanning anchor and an extended domain located on the inner side of 
the viral membrane. The functional motifs involved in fusion into the host cell have been extensively 
studied. Thus, four major regions are located at the ectodomain, which contains a hydrophobic, glycine-
rich N-terminal 20 residues fusion peptide (FP), a N-terminal heptad repeat (HR1), a C-terminal heptad 
repeat (HR2), and a tryptophan-rich region that governs the fusion. HR1 and HR2 are both domains prone 
to helicity, and between both heptad repeats a disulfide-bridged loop is located that docks gp120 into 
gp41 non-covalently. The transmembrane domain as well as the long cytoplasmic tail in gp41 modulates 
the conformation of external domains and subtly regulates their fusogenicity, playing both an indirect but 
fundamental role during the fusion. However, an exhaustive structural and functional description of gp41 
is out of the scope of this report and no further details will be specified.  
 
2.2. Entry process mechanism 
A brief overview to the entry process is essential for the thorough understanding of the role of 
gp120 and its importance. The HIV-1 entry into target cells is a dynamic, complex and multi-stage 
process that involves at least three phases: attachment of the virus into host cells via interactions between 
the viral glycoprotein gp120 and cell receptor CD4, further co-receptor binding on the host cell surface 
and finally membrane fusion mediated by the viral gp41 transmembrane glycoprotein (Figure 3). 
Despite its great complexity, the mechanism of HIV-1 entry into the host cell has been elucidated 
to a certain degree of detail [28]. The infection starts with the primary attachment of the virions to the 
target cells by unspecific interactions that permits the approach of both molecules. Then, specific 
interactions are established between the gp120 glycoprotein of HIV and the primary receptor CD4 
expressed in the surface of a variety of immune cells such as macrophages, T lymphocytes, dentritic cells 
and microglial cells. This gp120-CD4 binding induces conformational changes in gp120 facilitating the 
formation and exposure of a chemokine co-receptor epitope located at the surface of the glycoprotein. 
This high affinity binding site is located in the third variable loop (V3), therefore, the virus selectivity for 
CCR5 or CXCR4 co-receptors is mainly defined by the amino acids sequence located in the V3 loop 
region in gp120. After attachment to CD4, the V3 region of gp120 is projected towards the target cell 
surface. Subsequently, it has been suggested that the N-terminus of the co-receptor (CCR5 and/or 
CXCR4, depending on the virus tropism) reaches the bridging sheet at the base of V3. Further 
conformational rearrangements in V3 tilts this domain over the co-receptor extracellular loops that lead to 
the exposure of the fusion-peptide (FP) domain of gp41. The insertion of the hydrophobic NH2-terminus 
FP into the membrane of the target cell disrupts the lamellar organization of the host membrane 
phospholipids. In parallel with these events, gp41 triggers further fusogenic transformations. Thus, as the 
FP dart out the host membrane, it induces a folding and packing of the sensitive heptad repeat regions 
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(HR1 and HR2) in gp41, creating a pre-bundle intermediate that makes the disulfide bridge of gp41 
weaken its contact with gp120. The pre-bundle intermediate consequentially matures to a functional six-
helix bundle. This feature results in pulling the viral membrane close to the cellular surface and forming a 
viral pore that concludes with cell fusion and eventually leads to the release of the viral capsid into the 
cellular cytoplasm. Infection of HIV has formally started.  
 
 
Figure 3. Schematic mechanism of the proposed entry process of HIV virus into host cell. 
 
3. gp120 inhibitors 
The different families of inhibitors of gp120 will be organized and critically described in this 
overview according to their specific molecular target along the structure of the glycoprotein, each one 
associated to a well-defined mechanism of action.  
 
3.1. Polyanionic compounds 
The very first step in the attachment of HIV to the target cells has been demonstrated to involve 
unspecific electrostatic interactions comprising of negatively charged glycoproteins located on the surface 
of the host-cell membrane and a series of positively charged domains of gp120. In order to avoid these 
interactions, polyanionic compounds have been proposed as potential HIV entry inhibitors which could 
bind to the glycoprotein gp120 blocking the first contact and subsequently preventing the entry of the 
virus into the host cell [29]. In particular, it has been reported that a series of polymeric compounds 
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endowed with extensive negatively charged motifs on their structure could interact with the positively 
charged V3 region of gp120 in both CCR5 and CXCR4 tropism viruses. It is noteworthy that a higher 
affinity has been observed between polyanionic agents and CXCR4 HIV-1 viral strains, which could be 
explained by the presence of the more positively charged amino acids located in the V3 loop domain in 
this tropism, and consequently to the greater electrostatic interactions that might be established. 
Given the lack of target specificity and the pharmacokinetic issues associated to the polar nature 
of such inhibitors, polyanionic compounds did not progress as systemic anti-HIV drugs. However, this 
class of agents is endowed with good properties which could be used for topical prophylactics rather than 
oral administration. Thus, polyanionic compounds have been considered as attractive vaginal 
microbicides for reducing the risk of contracting HIV since the discovery of the illness. 
There are several potential polyanionic compounds microbicides described, all of them of high 
molecular weight with wide structural diversity and different sizes. Three of the most potent compounds 
reported in the literature are: sodium cellulose sulfate (1, Ushercell®), Carrageenan (Carraguard®, 
consisted of a mixture of κ- and λ-carrageenan, which are linear sulfated polysaccharides extracted from 
naturally occurring red seaweeds), and PRO 2000 (2, a naphthalene sulfonate polymer) (Figure 4). They 
all are active in vitro against a wide range of HIV-1 isolates in preventing the transmission of the virus 
from dendritic cells to target cells in nanomolar to micromolar ranges [30] [31] [32].
 
Recent studies 
determined the safety and good properties of these polymers formulated as gels in clinical studies [33] [34] 
[35]. However, they finally failed facing clinical phase III trials due to their low efficacy and in some 
cases, to the suspicion of an increasing risk of HIV-1 infection during frequent use [36] [37] [38]. 
Therefore, these promising polyanionic agents were discarded as vaginal microbicides and their clinical 
development has been discontinued. 
 
 
Figure 4. Polyanionic polymers for HIV-1 treatment. 
 
In an attempt to discover small molecules to avoid the problems associated during the 
administration of polymeric compounds, Suramin (3) emerged as the first small-size negatively charged 
agent directed to prevent the HIV-1 infection in vitro in human intestinal epithelial cells HT-29 (Figure 5) 
[39]. Suramin exploited the presence of sulfonate moieties profusely distributed on naphtalene rings 
further functionalized in a non-polymeric molecular structure.This polysulfonyl naphthylurea was initially 
proposed to inhibit the reverse transcriptase enzyme during the HIV-1 replicative cycle [40]; however, 
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further studies demonstrated that this compound really neutralized the HIV infection in an early stage and 
blocked the attachment of gp120 with the primary cell receptor [41]. HT-29 cells express the receptor 
glycosphingolipid galactosylceramide (GalCer) instead of CD4. Therefore, 3 specifically binds to the 
conserved region of the V3 loop of gp120 blocking the gp120-GalCer interaction with an IC50 value of ~ 
40 µM. Clinical trials of Suramin showed a decrease of the virus loads in infected patients but the toxicity 
and the adverse effects observed during the treatment of these patients forced the disruption of further 
investigations [42]. The original results obtained with Suramin nevertheless indicated the importance of 
these types of structures and research in this regard has continued.  
 
  
Figure 5. Small-size polyanionic inhibitors. 
 
Later, Lexigen Pharmaceuticals identified compound FP-21399 (4), a bis(disulfonaphthalene) 
derivative structurally related to Suramin, that showed micromolar inhibition ability against HIV-1 in 
infected and non-infected CD4
+
 cells (Figure 5). It has been demonstrated that FP-21399 targets gp120 
and binds to the positively charged V3 loop of the glycoprotein blocking the interaction with receptor 
CD4, as anticipated due to its negatively-charged nature [43]. Preclinical studies demonstrated low 
toxicity and no adverse reactions in animals and phase II trials showed a hint of immune response in 
infected patients [44]. However, further studies are still necessary to determinate its efficiency as no 
definitive conclusions could be established from the limited preliminary phase II trials. 
Continuing the trend of designing HIV drugs based on the bis-(disulfonaphthalene) structure, 
Debnath and co-workers synthesized the small polyanion ADS-1J (5) closely structurally related to FP-
21399 (Figure 5). It must be highlighted that this compound was originally designed from computer based 
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docking algorithms to potentially attach to glycoprotein gp41 and interfere with the binding to CD4 [45]. 
However, ADS-1J is an anionic compound and, as such, it would be expected to preferably interact with 
gp120 instead of gp41; therefore, there has been huge controversy about its mechanism of action over the 
last years and both gp120 or gp41 were proposed as therapeutic targets of 5 [46]. Very recent studies 
reported by Esté at al [47]. based on time-on-drug-addition and virus resistance experiments have finally 
clarified the inhibition step of this compound and it was concluded that it definitively behaves as a HIV-
gp120 inhibitor in vitro potentially via a polyanionic mechanism targeting the positively charged region 
of the V3 domain in gp120. 
Porphyrin derivatives are a structurally different family of polyanionic compounds that have 
gained much attention lately for the inhibition of the HIV-1 virus. Among them, the most potent members 
of this new family of therapeutics so far are iron (III) porphyrins Fe
III
P1 (6) and Fe
III
P2 (7) recently 
described by Kano et al.
 
[48] (Figure 6). These porphyrins exhibited a potent antiviral activity in vitro 
(EC50 = 0.059-1.7 µM) and low cytotoxicities. The iron atom seems to play a capital role in the high 
selectivity of these porphyrins to attach to the V3 loop in gp120. Despite these promising results and 
attractive prospects, poor absorption into the blood stream as well as  strong binding to the serum albumin 
in rats were observed in preclinical trials for both compounds 6 and 7, which are both seen as major 
drawbacks. Therefore, further enhancement of the pharmacokinetic properties should be performed for 
future systemic use of these anti-HIV-1 candidates, while their application as microbicides is promising 
and is currently under study. 
 
  
Figure 6. Metallated-porphyrin derivatives. 
 
Sodium glycyrrhizin sulfates like 8 are another polyanionic family that emerged as novel anti-
HIV agents in the late 1990s able to inhibit the HIV-1 replication in vitro in the micromolar range (Figure 
7) [49]. The attention focused in these compounds was owing to their amphyphylic nature (as they consist 
of both hydrophobic (triterpenoid group) and hydrophilic regions (sugar moiety)) and the direct 
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relationship established between the ability to form micelles and the anti-HIV activity. Details about the 
mechanism of action of these agents have not been given but they are proposed to act in an early stage of 
the replication cycle of the virus. Moreover, due to their polyanionic nature it could be suggested that they 
act in a polyanionic mechanistic fashion. 
 
 
Figure 7. Sodium glycyrrhizin sulfates derivatives. 
 
Aurintricarboxylic acid (ATA) has been found to be a potent and selective inhibitor of HIV-1 
replication in vitro in MT-4 cells (IC50 = 5 µM) [50]. Originally described as a single triphenylmethane-
type compound, this monomeric form readily polymerises in aqueous solution. Thus, ATA is comprised 
really of a heterogeneous mixture of polymeric structures schematically portrayed as 9 (Figure 8). When 
the polymeric mixture of 9 was separated into different fractions, it was demonstrated that exits a 
correlation between its potency with the average molecular weight. A similar behavior was observed 
when the sulfonic and phosphonic acid derivatives of ATA were studied. Thus, the higher the molecular 
weight, the higher the anti-HIV activity observed [51]. Moreover, under physiological conditions, ATA 
should be a polyhydroxycarboxylate negatively charged molecule and its inhibitory activity seems to 
depend on the presence of these anionic carboxylate groups, since the protected methyl ester derivatives 
are uniformly inactive [51b]. The anti-HIV-1 activity of the ATA fractions has been postulated to be 
presumably due to inhibition of gp120-CD4 interaction, targeting both viral glycoprotein as well as cell 
receptor, although the interaction with gp120 in the absence of CD4 binding is sufficient for anti-HIV 
activity.  
Taking into account the information given about polyanionic compounds for the inhibition of 
gp120, it can be concluded that they are still far from being clinically approved for HIV-1 therapy. While 
polyanionic polymers have shown low efficiency in clinical trials, small size negatively charged 
compounds are still under development and studies regarding their pharmacokinetics properties are 
urgently required. However, the remarkable potent anti-HIV activity shown in several small polyanionic 
compounds indicates that they could have a great potential as vaginal microbicides. 
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Figure 8. Aurintricarboxylic acid (ATA). 
 
3.2. Carbohydrate-Binding Agents (CBAs): glycans of HIV as targets 
Recently, an entirely novel strategy against human immunodeficiency virus HIV-1 has emerged 
proposing the glycans of the viral envelope glycoprotein gp120 as the primary molecular targets [52]. This 
approach is highly original as it is not the peptide portion of the protein but the carbohydrates located at 
the surface which constitute the goal of a new family of promising therapeutic agents described 
generically as Carbohydrate-Binding Agents (CBAs). CBAs are able to efficiently block HIV-1 infection 
and furthermore the viral transmission by exerting their activity at the early steps of the replicative cycle 
by binding reversibly to the envelope glycans of gp120.  
An essential feature of the CBA approach is its dual nature. In a first stage, the inhibitory 
behavior of CBAs against HIV-1 relies on the recognition of and binding to specific sugar moieties 
located in the surface of gp120. Multiple non-permanent low-intensity interactions are established 
between the CBA and the envelope oligosaccharides that eventually originate cross-linked structures, 
which affect the mobility of the env proteins and prevent the conformational changes required to initiate 
the entry process into their target host cell. It should be also noted that binding between sugars and CBAs 
might be advantageous as they can target multiple HIV strains and tropisms sharing a similar 
carbohydrate array. 
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On the other hand, it is expected that long-term therapeutic pressure due to CBA forces the virus 
to mutate, which results in the emergence of drug resistance. Globally, HIV-1 selects for virus mutant 
strains which present deletions of N-glycosylation sites [53], which change the glycosylation pattern of 
gp120 and could produce a less dense glycan shield. This feature makes more accessible previously 
hidden critical immunogenic epitopes, triggering an enhanced recognition and further eradication by 
neutralizing antibodies of the innate immune system. In this sense, Reitter et al. [54] have proved in vivo 
that mutant simian immunodeficiency virus (SIV) strains lacking only two N-glycosylation sites in their 
external envelope protein show a marked increase in antibody formation and a considerable decrease in 
viral load. A very recent contribution asserted that occluding mannose moieties in HIV-1 monomeric 
gp120 can improve the humoral immune response to this protein in mice [55]. Moreover, it has been 
reported that glycan deletions in the HIV-1 gp120 V1/V2 domains severely compromise viral infectivity 
and sensitize the mutant virus strains to carbohydrate-binding agents [56]. Furthermore, some specific N-
glycosylation sites are indispensable for efficient viral entry (such as Asn
260
) [57]. Thus, a resistance 
pattern directed to the elimination of N-glycosylation sites of gp120 could be of interest in enhancing  
immunosuppression of the pathogen.  
This depicted dual mode of action is unique and makes CBAs a conceptually novel class of anti-
HIV-1 agents that merges a direct chemotherapeutic action that induces for an unusually specific and 
selective drug resistant profile, which eventually could trigger the immune system to recognize previously 
hidden epitopes of the virus. Furthermore, CBAs prevent not only virus infection of susceptible cells, but 
also inhibit specific interactions between viruses and lectins of the immune system that lead eventually to 
the formation of syncytia that are used by the virus for transmission between persistently HIV-infected 
cells and uninfected lymphocytes This may in turn result in the more efficient elimination of infectious 
HIV-1.  
It must be noted that the CBA strategy could also be directed against other glycan-containing 
enveloped viruses [58]. In fact, it has been recently demonstrated that CBAs, including several plant 
lectins and the non-peptidic small-size antibiotic Pradimicin A (see section 3.2.2. below) efficiently 
prevented hepatitis C virus (HCV) and HIV-1 infection of target cells by inhibiting the viral entry through 
their interaction with viral envelope-associated glycans [59], which may represent an attractive new option 
for therapy of HCV/HIV co-infections. 
The term CBA was introduced by Balzarini and currently conceptually describes a 
heterogeneous series of compounds with carbohydrate-binding capacity that comprise a broad and 
structurally diverse functional class of agents including both macromolecular Carbohydrate-Binding 
Proteins (CBPs) as well as naturally-occurring or synthetic, non-peptidic, small-size CBAs. [53c] 
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3.2.1. Carbohydrate-Binding Proteins (CBPs) 
Several examples of naturally occurring Carbohydrate-Binding Proteins (CBPs) exists in the 
specialized literature whose anti-HIV activity have been reported with potencies as low as the picomolar 
range [60]. Among them, it must be highlighted a wide, heterogeneous family of high-molecular weight 
proteins generically called lectins. Lectins can be derived from a variety of species in nature, including 
prokaryotics, sea corals, algae, fungi, higher plants, invertebrates and vertebrates. All of them share a 
common mechanism of action against HIV-1 based on the ability to bind to specific carbohydrate motifs 
present in gp120 in a highly selective fashion. However, in spite of their potential, only a few of them 
have been validated as candidates for clinical studies. In this review, we will overview a few 
representative examples of CBPs able to bind glycans of gp120 and neutralize HIV-1. 
The best known and most studied CBP with remarkable activity against HIV-1 is Cyanovirin-N 
(CV-N). CV-N recently attracted great interest because of its broad range of antiviral activity in most 
laboratory HIV-1 (EC50 < 1 nM) and HIV-2 (EC50 ≥ 2 nM) strains. It has been shown its ability to inhibit 
HIV infection in ectocervical human explants with remarkable selectivity [61]. Actually, CV-N is the only 
lectin so far tested in in vivo transmission models and its potential as a microbicide has been positively 
evaluated in macaque models [62]. This 11 kDa lectin was first isolated from the cyanobacteria Nostoc 
ellipsosporum and consists of a single 101 amino acid chain [63]. It blocks HIV entry by specifically 
binding to terminal high-mannose oligosaccharides containing Manα(1-2)Man motifs, located 
predominantly in the C2-C4 regions of the viral glycoprotein gp120 [64]. In preclinical studies, 
formulated as a microbicide in the form of a vaginal gel for the prevention of sexual transmission of HIV 
infection, CV-N demonstrated no cytotoxicity or noticeable adverse effects. However, in spite of its 
potent antiviral activity, safety issue concerns were recently raised about its use as it has been 
demonstrated that it induces the expression of chemokines that eventually reached a stimulatory activity 
in PBMC cultures [65]. Additionally, Buffa et al. [66]. corroborated that CV-N produces some mitogenic 
effect in a time-dependent fashion if the exposure to the microbicide exceeds of 24 h. Due to these 
drawbacks, preclinical studies on CV-N have been discontinued.  
Microvirin (MVN) is a novel 12.7 kDa lectin comprised of a 108 amino acids sequence recently 
isolated from the cyanobacterium Mycrocystis aeuriginosa [67]. It is related to CV-N, exhibiting a similar 
three-dimensional CV-N-type fold.[56b]
 
 It also exhibits specificity for Manα(1-2)Man motifs, the 
disaccharide unit that commonly terminates the arms of the high-mannose N-linked oligosaccharides in 
gp120 like CV-N does. Thus, MVN has become a more promising candidate for clinical studies with a 
remarkable anti-HIV-1 activity, comparable to that reported for CV-N but exhibiting a much higher safety 
profile [68]. 
Griffithsin (GRFT) is another lectin recently isolated from seaweed (Griffithsia sp.) [69] with a 
molecular weight of 12.7 kDa and a sequence of 121 amino acids [70]. Structurally, GRFT adopts an 
active domain-swapped dimeric 25 kDa form and each monomer has three almost identical carbohydrate-
binding sites that bind oligomannose glycans, targeting specifically terminal mannose residues found on 
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high-mannose cores. GRFT is to date the most potent anti-HIV algal lectin described so far, showing 
activity against both HIV-1 and HIV-2 laboratory strains with EC50 values in the picomolar range. GRFT 
showed also potent antiviral activity against different HIV-1 clade clinical isolates and it exhibited a 
potent inhibitory capacity when tested in ex vivo cervical explants models. Recently, Férir et al. [71] 
combined GRFT with the nucleotide reverse transcriptase inhibitor Tenofovir, the CCR5 HIV co-receptor 
antagonist Maraviroc and the gp41 fusion inhibitor Enfuvirtide and all combinations were synergistic 
against HIV-1 clade B and clade C isolates in PBMCs and in CD4
+
 MT-4 cells. It has been also 
demonstrated that GRFT can be used in combination with other CBPs that recognize multiple and often 
distinct glycan structures on the HIV envelope gp120 and therefore do not necessarily compete with each 
other’s glycan binding sites. These combinations showed synergistic activity against HIV-1 and available 
information to date is encouraging for the use of paired CBA combinations in topical microbicide 
applications to prevent HIV transmission [72]. Currently, GRFT is proposed as a candidate microbicide 
agent due to its great potential [73]. 
In a recent contribution, LiWang and co-workers [74] analyzed the role of the three individual 
carbohydrate-binding sites (CBS) in GRFT. Thus, a series of mutations were induced in the protein led to 
alter the individual CBS and the mutated variants of GRFT were studied by NMR and their binding 
affinity for gp120 glycans quantified by Surface Plasmon Resonance (SPR). Modification of any 
individual CBS on GRFT reduced binding of the protein to mannose, with a near-complete loss of 
binding by the triple mutant which alters simultaneously all the CBS. The single CBS point mutants of 
GRFT were significantly less able to inhibit viral infection, exhibiting a loss of HIV inhibitory potency 
(up to 1900-fold) compared to the wild-type protein.  
In a meritorious attempt to simplify the large structure of GRFT, Ruchala et al. [75] recently 
identified Grifonin-1 (GRFN-1), a novel 18-residue peptide that exhibited remarkable anti-HIV-1 activity. 
This oligopeptide is derived from a trio of homologous β-sheet repeats that comprise the motifs 
responsible for the carbohydrate binding of the parent protein GRFT, and by extension, of its biological 
activity. Like its parent protein, GRFN-1 bound viral glycoprotein gp120 via the N-linked glycans on its 
surface as demonstrated by SPR experiments but with a 6-fold smaller molecular size. Its low toxicity, 
limited secondary effects and remarkable activity against both CCR5 and CXCR4 HIV-1 strains together 
with its relatively small size suggest that GRFN-1 and/or related derivatives may have therapeutic 
potential for further development as HIV-1 entry inhibitors for topical (microbicide) or systemic 
applications. 
Globally, CBPs could be considered a novel and unique family of anti-HIV chemotherapeutic 
agents. Therefore, extraordinary efforts have been made into the identification of new lectins as well as 
into the achievement of a deep understanding of their functions and of the precise mechanism of their 
association with specific carbohydrate ligands. However, in spite of this enormous potential, particularly 
as microbicides, lectins still exhibit certain disadvantages associated to their protein nature and high 
molecular weight. They have intrinsically unfavorable properties such as complex production and 
difficult purification in large scale, high manufacturing costs, poor or any oral bioavailability, low 
stability (susceptible to proteases) and pose potential risks for initiating unfavorable immune responses or 
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secondary effects. Hence, their development and use as suitable drugs may be compromised. Therefore, 
nowadays there is increasing interest in the search for synthetic low-molecular weight carbohydrate-
binding agents (CBAs) behaving as “lectin-mimetics”, capable of acting through a similar mechanism to 
that of the natural lectins but without their associated limitations. 
 
3.2.2. Nonpeptidic CBAs 
In the last decades, the development of synthetic ligands directed to the selective recognition of 
carbohydrates in water has emerged as a challenge for chemists [76]. Mimicking the interaction and 
binding motifs observed in the protein-carbohydrate complexes (non-covalent interactions such as 
hydrogen bonding, CH-π interactions, etc.), it has been possible to roughly establish the molecular basis 
that might assist in the design of artificial carbohydrate receptors [77]. However, the reported artificial 
carbohydrate receptors have only been rarely studied as antivirals in the CBA strategy context. In contrast 
with the huge amount of literature available on CBPs (molecular weights ranging between 9 and 50 kDa), 
there are only a few reports on non-peptidic small-size CBAs endowed with antiviral activity.  
In this respect, a few compounds belonging to the Pradimicin/Benanomicin families of 
antibiotics behave like the above-mentioned lectins. Originally developed as antifungal agents, 
Pradimicins are secondary metabolites based on a structure of benzo[a]naphtacenequinione containing a 
pattern of substitution that include amino acid residues and a monosaccharide/disaccharide core located at 
the periphery of the molecule (Figure 9). Interestingly, Pradimicin A (PRM-A, 10, Mw = 895), isolated 
from the actinomycete Actinomadura hibisca [78] exhibited a selective inhibitory activity in cell cultures 
against a variety of HIV-1 clades regardless of the tropism of the virus at a low micromolar range [79]. 
The outstanding aspect of PRM-A is related to its mechanism of action, as its antiviral activity can be 
ascribed to the recognition of terminal D-mannopyranosides moieties of gp120 in a Ca
2+
-dependent 
manner, blocking the entry process of HIV-1 into the host cell in a similar way to that described for 
lectins. Very recently, solid-state studies performed on PRM-A and BMY-28864, a water soluble 
analogue of PRM-A [80], provided direct experimental evidence that allowed for the proposal of a model 
of binding in which the amino acid residue of PRM-A is the main binding region through coordination 
with the calcium ion and involving also rings A, B and C of two units of the antibiotic, leading to a 
[(PRM-A)2/Ca
2+
/Mannose] complex [81] 
On the other hand, PRM-A has been found to exhibit the expected mutational pattern (selecting 
for N-glycosylation deletions) and good resistance profile, two of the crucial lectin properties. However, 
during preclinical trials, one of the main drawbacks of PRM-A was its remarkable poor aqueous 
solubility. To circumvent this limitation, Pradimicin-S (PRM-S, 11) [82], a Pradimicin-A analogue that 
contains an extra negatively charged 3-sulfated glucose in its structure obtained by a related 
microorganism (Actinomadura spinosa), was evaluated (Figure 9). This analogue behaves quite similarly 
to PRM-A in terms of antiviral activity, glycan recognition and drug resistant-induced profile but with 
better pharmacokinetic properties, allowing not only its formulation as a microbicidal agent but also for 
potential systemic use. Hence, it is considered a good candidate for preclinical and clinical studies. 
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A very recent contribution due to Bewley and co-workers [83] took advantage of the increased 
solubility of PRM-S to study its assembly and carbohydrate recognition under physiological conditions. 
Thus, by using an integrated approach that included NMR, analytical ultracentrifugation, SPR and viral 
neutralization assays, authors conclusively demonstrated that PRM-S is able to form discrete Ca
2+
-
dependent oligomers that, additionally, show extremely high selectivity for the mannotriose core structure 
Man1−6(Man1−3)Man that is a structural motif present in all high-mannose oligosaccharides. More 
importantly, this study is complementary to other recent contributions [80] [81] and could contribute to 
reveal the requirements for carbohydrate recognition by small molecules that may could be used in the 
future design of novel synthetic CBAs based on the Pradimicin family of compounds. 
 
 
Figure 9. Structures of potential small-size synthetic carbohydrate-binding agents. 
 
Recently, Alcian Blue (AB, 12), a phtalocyanine derivative, has been also described to inhibit 
the infection of a wide spectrum of HIV-1 strains in various cell cultures through a proposed mechanism 
involving the reversible binding to N-linked glycans of gp120 (Figure 9) [84]. Prolonged treatment with 
AB resulted in the selection of mutant virus strains in which several N-glycosylation sites of gp120 have 
been deleted. In this respect, AB closely mimics the antiviral mechanism of action and resistance profile 
of the plant and prokaryotic lectins. This is the first reported fully synthetic molecule that behaves like a 
CBA, which has a great conceptual significance. However, although AB undoubtedly targets the glycans 
on the envelope of HIV-1, this may not be its sole mode of antiviral activity. It is remains currently 
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unclear which is the specific sugar/oligosaccharide that AB targets in the glycan array of gp120 and 
whether its antiviral activity could be also associated to other complementary interactions with molecular 
targets which play a direct or indirect role in the entry process of HIV. Further studies should be 
performed to clarify these subjects.  
In 2011 Pérez-Pérez et al. [85] reported a new family of synthetic small-size CBAs based on a 
1,3,5-triazine central core functionalized with aromatic amino acids which were differently branched 
(monomeric, dimeric and trimeric species) and were designed to mimic interactions that lectins establish 
with gp120. The best results were observed for trimeric compounds of general structure 13 (Figure 9). 
These molecules were shown to be active in the micromolar range (EC50 ~ 20 µM) against diverse HIV 
isolates in vitro in CEM T-cell lines and no cytotoxicity was observed (CC50 > 250 µM). It must be 
highlighted that monomers were inactive against HIV replication and dimers exhibited only moderate 
activity, while the trimeric series were the most active compounds of the series. This clearly shows that 
the introduction of several ligand subunits in synthetic CBAs could compensate for the lability of the 
individual non-covalent bindings with the carbohydrates by the establishment of concomitant multiple 
interactions (multivalency [86]), as usually observed in lectins [61c] [87]. Surface Plasmon Resonance 
(SPR) studies verified that 13 inhibited the HIV-1 infection in an early step of the replicative cycle by 
binding to gp120, presumably due to interaction with surface carbohydrates; however, the exact 
mechanism of action is still under investigation. 
These findings prove that CBAs with non-peptidic nature and low molecular weight able to 
reversibly bind to carbohydrates located at the surface of gp120 can exert a similar therapeutic effect to 
that exhibited by CBPs. This may have important repercussions as it provides both an encouraging proof-
of-concept and a rational basis for the design and further exploration of this potential class of 
chemotherapeutics. Further investigations are needed to reveal whether or not these compounds are able 
to block HIV-1 infection in vivo.  
Another strategy which has been used for the design of synthetic CBAs involves the exploitation 
of non-natural bonding interactions as an alternative to the low-intensity noncovalent binding mimicking 
the natural lectins. This approach fundamentally relies on the reaction between cis-diols (profusely 
observed in the surface carbohydrates in gp120) and boronic acids or derivatives that eventually give 
cyclic structures such as boronates [77a] [88]. Over the past years, a number of research groups have 
attempted to develop synthetic carbohydrate receptors that could be selective for the recognition of cell-
surface oligosaccharides with therapeutic potential (boronolectins) [89]. 
A practical strategy in this field exploits the attachment of multiple carbohydrate ligand motifs to 
oligomeric or polymeric backbones specifically for binding to glycans of gp120. In this regard, a recent 
contribution is due to Kiser et al. [90]
 
, who described a series of water-soluble polymeric structures 
including several benzoboroxoles as potential carbohydrate ligands. It has been stated that 
benzoboroxoles are able to bind to terminal nonreducing hexopyranoside residues, which are structurally 
similar to those present in high-mannose and complex-type N-linked glycans of gp120. More importantly, 
the interaction takes place in neutral aqueous environments. While benzoboroxole groups independently 
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showed weak affinity for gp120 as demonstrated by SPR studies, the incorporation of this small ligand 
core molecule into oligomeric backbones created polyfunctionalised structures which strongly increase 
the affinity due to a multivalent effect. Thus a 25% mol benzoboroxole-functionalized polymer exhibited 
a moderate activity (EC50 = 15000 nM) while a 75% mol polymer increased its activity against HIV-1 to a 
nanomolar range (EC50 = 11 nM). These polymers demonstrated a broad spectrum of activity (against all 
viral strains and both co-receptor tropism) and similar efficacy in vitro as CN-V and no noticeable 
cytotoxicity was observed after exposure to human vaginal cell lines for 24 h. The mechanism of action is 
still not completely clear but it has been hypothesized that they can prevent binding of gp120 to either 
receptor CD4 or co-receptor CCR5 through covalent attachment to sugars present at the surface of the 
patogen’s env gp120 protein. Interestingly, as lectins, these compounds demonstrated selection for mutant 
HIV-1 strains that contain deleted N-glycosylated sites on the envelope of gp120, supporting additionally 
a CBA-type mechanism of action.  
The great potential of these compounds impelled Kiser and co-workers to extend the study [91]. 
Recently, high molecular weight benzoboroxole-functionalised polymers demonstrated antiviral activity 
that rises with increases in ligand density, endorsing that multivalence strongly improves activity. The 
highest activity was seen with a 382 kDa polymer (EC50 = 1.1 nM in CEM cells). However, the larger 
polymers showed poor aqueous solubility. In order to overcome this problem, a co-polymer containing 
sulfonic acid groups (10% mol) was synthesized and this increased 100-fold the polymer solubility while 
maintaining activity in the same range (1-4 nM, similar to CV-N). Mechanistically, it has been proposed 
that the polyanionic polymer backbone would first establish unspecific electrostatic interactions with the 
positively charged V3 loop of gp120 (such as polyanionic agents, see section 3.1.), thereby facilitating 
further covalent interactions between the benzoboroxole and the glycans on gp120. Although the 
molecular weight of these polymers is comparable to that of the proteins, they endow remarkable 
advantages over CBPs such as practical and affordable production, broad-spectrum activity and ease of 
formulation. Therefore, these polymers may act as potential microbicides. 
 
3.3. Targeting CD4 binding site on gp120 
One of the most obvious and straightforward ways to prevent the HIV infection is to inhibit the 
binding of the virus to its primary receptor on the host cell. Thus, compounds that could interfere in the 
CD4 binding site in gp120 would be attractive candidates to block HIV entry process and represent the 
most important group of gp120 HIV inhibitors currently under study. The huge interest in these anti-HIV 
agents is also given to the absolute functional conservation of the CD4 binding site in gp120 among all 
isolates of HIV-1 and it has been hypothesized to be a site less prone to resistance-conferring mutations 
[92]. 
Soluble versions of the receptor CD4 (sCD4) were first analyzed as candidates for HIV entry 
inhibitors to block the gp120-CD4 attachment. The free recombinant protein sCD4 exhibited potent 
inhibitory activity against HIV-1 laboratory strains [93]. However, in vivo experiments revealed that sCD4 
was rapidly removed from the peripheral blood and was not active enough to decrease viral loads in a set 
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of HIV-1 infected patients [94]. In order to improve their pharmacokinetic properties and efficacy, several 
CD4 mimetics emerged as potential HIV-1 therapeutics. Among them, oligomeric CD4-IgG fusion 
proteins gained much consideration, such as PRO 542, which merges human immunoglobulin IgG2 and 
HIV-binding domains of CD4. It showed potent neutralizing and antiviral activity in vitro and ex vivo, 
reaching phase I/II trials [95]. Simultaneously, approaches based on the design of soluble recombinant 
CD4 proteins presenting amino acids mutations in specific sites or small amino acid peptides mimicking 
the CD4 are very significant as these agents are able to enhance the efficacies of gp120-targeted therapies 
and env-based immunogens [96]. However, in the recent years more attention has been paid to the 
identification of small-molecule inhibitors that prevent the binding of gp120 to CD4 receptor for the 
treatment of HIV-1 and many efforts have been directed to identify new non-peptidic low molecular 
weight agents. 
A detailed understanding of the interaction between gp120 and CD4 has helped to design small 
size CD4 mimics. A significant development was the elucidation of a resolved X-ray crystal structure of 
gp120-CD4 complex that exposed in high detail the presence of a hydrophobic cavity in the interface of 
CD4 and gp120 which is formed by elements of the major domains and bridging sheet of gp120, and is 
occupied by a single CD4 aromatic residue, a phenylalanine located in position 43 (Phe
43
) [17]. This deep 
depression has been referred to as the Phe
43
 cavity. Surrounding it, there are positively charged residues 
that make direct contact to CD4 but have a minor contribution to the gp120-CD4 interaction. Hence, 
compounds that target the Phe
43
 cavity have been suggested as desirable drug candidates that inhibit HIV-
1 by blocking the CD4-gp120 attachment. 
The first promising small molecule described in the literature able to interfere in the gp120-CD4 
receptor interaction was BMS-378806 (14) (Figure 10), an azaindole derivative discovered by a Bristol-
Myers Squibb team [97]. The interest of this candidate was owing to its good oral bioavailability and 
excellent safety profile together with a potent antiviral activity in laboratory cells cultures. However, 
during phase I clinical trials it showed an inadequate plasma exposure in healthy human volunteers. Due 
to this drawback, development of BMS-378806 was discontinued and alternatively detailed structure-
activity studies (SAR) were performed in order to find a better candidate for the HIV-1 treatment based in 
this lead compound [97b] [98].  
In this context, BMS-488043 (15) containing a 7-azaindol core emerged as a new generation 
derivative of the parent compound 14 with an analogous mechanism of action [99]. It presented enhanced 
in vitro antiviral activity improved to the nanomolar range and a better in vivo pharmacokinetic profile, 
such as a longer half-life (t1/2) and better permeability in the gastrointestinal tract (Figure 10) [100]. 
Despite these improvements, its oral administration was still limited to both high doses and the 
requirement of a high-fat meal in order to reach enough plasma levels in infected patients. A practical 
solution to this problem was recently proposed by Kadow et al. [101] using a prodrug approach. Thus, 
BMS-488043 was formulated as its phosphonooxymethyl lysine salt, BMS-663749 (16) (Figure 10). This 
prodrug was effective in delivering the parent drug and it was rapidly absorbed in plasma, overcoming the 
problems related to 14. However, the clinical pharmacokinetics properties were still far of being ideal and 
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BMS-663749 was discarded for further development for the treatment of HIV-1. Therefore, no BMS 
compound finally progressed on clinical trials.  
 
 
Figure 10. Potent CD4 mimics for HIV-inhibition. 
 
The detailed mechanism of inhibition of these compounds remains unclear still and huge debate 
has arisen around it. It seems nowadays accepted that this family of inhibitors bind to a specific hot-spot 
domain in the CD4 binding pocket of the viral gp120, attributed to the previously depicted Phe
43
 cavity, 
preventing its interaction with CD4 [102]. This mechanism could be supported by the fact that BMS-
378806 induces mutations in gp120 that are located very closely to the CD4-binding pocket [102] [103]. 
Alternatively, other authors suggested that BMS-378806 really acts in a more subtle way interfering in 
the gp120-gp41 conformational changes triggered after the attachment to CD4, so as to preclude an 
efficient rearrangement that finally hampers the entry of the virus [104]. 
As depicted above, no BMS candidate has made progress in advanced clinical phases. In spite of 
these discouraging results exposed for the Bristol-Myers Squibb azaindol family, they demonstrated 
excellent antiviral activity and hence, they constituted a proof-of-concept that establishes the interaction 
between gp120 and the host receptor CD4 as a viable target and the conserved CD4 binding site in gp120 
(Phe
43
cavity) as a promising hotspot for the design and development of novel small-molecule entry 
inhibitors. 
Simultaneous to the discovery of the BMS-family of gp120-CD4 inhibitors, another potent 
family was developed by Pfizer laboratories based in the BMS chemotype structure [105]. They focused 
their attention on the replacement of the chemically and metabolically vulnerable di-ketone group in the 
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parent drugs. Compounds 16 and 17 were identified as a result of an exhaustive SAR study
 
which 
exhibited antiviral activity in the nanomolar range in a wide panel of viral strains and good oral 
bioavailability in rats (Figure 10) [105a,b].
 
Although 17 was 10-fold more potent than 18, the predicted 
human pharmacokinetics for 18 were superior. It was therefore suggested that 18 it should be 
administered in twice daily doses revealing a better potential for HIV-1 treatment, which is nowadays 
under clinical development. More interesting was the discovery of compound 19 by the same company 
that was shown to be very potent in vitro with an IC50 value of 40 pM, which has no precedent for the 
inhibition of the CD4-gp120 attachment so far (Figure 10) [105d]. However, still preclinical and clinical 
studies are pending for the use of this promising agent in the HIV-1 therapy. 
Diverse families of HIV-1 inhibitors have been described sharing the same mechanism of action 
as BMSs, although exhibiting less potency, whose importance further relies on their novel chemical 
structure and could constitute good starting points for the development of new generations of structurally 
diverse gp120-CD4 inhibitors. For instance, in 2009 Botta et al. [106] reported compound 20 using a 
computational protocol as an anti-HIV-1 agent which was shown to inhibit virus replication in human 
lymphocyte MT-4 cell cultures at IC50 values of 9 µM at subtoxic concentrations (Figure 11). Its 
particular structure promotes the formation of hydrophobic and hydrogen bond interactions with specific 
residues in the Phe
43
 cavity; therefore interfering in gp120-CD4 protein-protein interactions. Another 
example comes from Gilon and co-workers that developed a novel method to convert the non-continuous 
active regions in CD4 into small macrocyclic molecules with anti-HIV-1 activity [107]. Compound 21 
was shown to inhibit HIV-1 infection in the low-micromolar range in vitro and had excellent oral 
bioavailability and good metabolic stability (Figure 11). Despite these promising properties and its 
interesting structure, it presented restricted ability to cross biological membranes and further optimization 
of the pharmacokinetic properties are still needed for further progress. 
A different family of agents were identified in 2005 by Debnath et al. [108] using database 
screening techniques. NBD-566 (22) and NBD-557 (23) were selected as the leading compounds of a 
chemical library containing a structural common oxalamide core (Figure 11). Molecules 22 and 23 
showed micromolar antiviral activity in cell-cell fusion and virus-cell fusion in a variety of cell lines in 
X4 and R5 tropisms. Surface Plasmon Resonance studies (SPR) and a recent co-crystal structure of 
gp120-22 confirmed a unique interaction between gp120 and 22 consisting of the projection of the 
aromatic ring of the NBD chemotype into the Phe
43
 hydrophobic pocket in gp120, therefore, competing 
with CD4 binding [108] [109]. However, a different mechanistic evolution follows the attachment to the 
Phe
43
 cavity. Contrary to the BMS-family, NBD compounds induce subtle conformational changes in 
gp120 that allows for the premature exposure of the CCR5/CXCR4 binding site. These conformational 
changes generate a short-lived activated state of the virus that rapidly converts into non-active 
conformations producing as a result the inhibition of the HIV infection. This intimate novel mechanism of 
action reached great expectations. However, the limited viral neutralization breadth and moderate 
antiviral activity exhibited by both NBD compounds precluded further developments but prompted to 
numerous groups to continue investigations. In this context, first attempts directed to modify the phenyl 
ring,
 
oxalamide linker and piperidine regions on NBD-556 led to a family of compounds with no 
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significant improved potencies. [109b] [110]. A remarkable advance in the NBD family was due to Amos 
Smith III, who very recently designed a structurally related compound 24 that showed a substantial 
improvement in the antiviral and neutralization potency of the parent compound among several viral 
isolates (Figure 11) [111]. This new compound contains a guanidinium motif replacing the piperidine ring 
that permitted the establishment of an additional electrostatic interaction between the guanidinium and the 
residue Asn
368
 in gp120. Therefore, 24 targets two binding hotspots in gp120 at the same time: the 
hydrophobic Phe
43 
cavity (common to the NBD chemotype family as previously mentioned) and the new 
ionic interaction with Asn
368
. Simultaneously to this paper, Debnath et al. [112] reported compounds 
NBD-11009 (25) and NBD-11018 (26) that exhibited the best potencies so far for the in vitro inhibition of 
HIV-1 of the whole NBD structurally-related family (IC50 = 1-2 µM) (Figure 11). As in the previous case, 
this improvement was due to the creation of multiple interactions between residues in gp120 and the 
novel NBD agent that strengthen the overall interaction at the binding site. Therefore, as these recent 
examples clearly state, there is still scope to develop novel small-molecule inhibitors of HIV-1 based in 
the NBD chemotype. 
 
 
Figure 11. Moderate HIV-1 inhibitors of the CD4-gp120 interaction. 
 
As previously detailed, both compounds NBD-556 (22) and NBD-557 (23) promote 
conformational changes in gp120 that lead to the exposure of the chemokine co-receptor CCR5/CXCR4 
binding sites. In order to obtain NBD-related compounds with better potencies, Tamamura and co-
workers designed a strategy based on the conjugation of 22 and other CXCR4 antagonists, reaching 
hybrid molecules such as 27 that exhibited enhanced EC50 values (nanomolar range) compared to simple 
CD4 mimics as a result of a significant synergetic effect (Figure 12) [109 a,b].
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Figure 12. Dual inhibitors. NaI = L-3-(2-naphthyl)alanine; Cit = L-citrulline. 
 
This type of strategy that connects two different inhibitors, specifically a CD4 mimic and a 
chemokine co-receptor antagonist, has been widely used to generate dual HIV-1 inhibitors. The main 
benefits are: better effectiveness, lower drug dosage and the reduction of the capacity of the virus to 
develop drug resistances as these agents simultaneously act against complementary therapeutic targets. 
Chaiken and co-workers recently reported a five-residue peptide 28 with a central triazol ring that 
inhibited the binding of gp120 to both CD4 and CCR5/CXCR4 sites and neutralized HIV infection 
(Figure 13) [113]. Although it exhibited only moderate activity (IC50 = 33 µM) in vitro, the novelty of this 
compound is related to the central ferrocene ring core, never used before in the design of HIV inhibitors. 
This is believed to be part of a spatially arranged aromatic cluster that interacts with sterically restricted 
sites in gp120 while the N-terminal extensions of the residues stabilize binding to the protein by 
additional hydrogen bond interactions. The result is the discovery of a completely novel series of 
allosteric inhibitors that target small epitopes in gp120, unlike the direct binding to the Phe
43
 cavity in 
gp120 observed in the previous CD4 mimics that compete for the site of attachment to CD4. Therefore, 
these developments open a promising window to the development of new inhibitors of gp120 acting 
through a completely novel mechanism to those described to date. 
Better potencies were obtained when dual compounds were obtained by linking a small CD4-
mimetic peptide to either heparin sulfate (HS) or a sulfated tridecapeptide that mimics HS rendering 
mCD4-HS12 and mCD4-P3YSO3 respectively [114]. These negatively charged compounds have the ability 
to interact with both the positively charged V3 loop (polyanionic unspecific mechanism) and the 
proximally located CD4 binding site in gp120, displaying a strong anti-HIV-1 activity in the low-
nanomolar range in cellular cultures independently of the HIV tropisms. Although they have a relative 
large molecular mass (5-6 kDa), they are still small in comparison to sCD4/CD4 mimetics nowadays 
described for the inhibition of HIV-infection. Moreover, the potent and broad antiviral activity confers it a 
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great potential to be used in the prevention and treatment of HIV, but further in vivo work and clinical 
applications are needed. 
 
 
Figure 13. Dual antagonists of HIV-1 gp120. 
 
3.4. Targeting co-receptor binding sites on gp120 
Another key interaction during the entry process of the HIV-1 into the host cell is between the 
CD4-gp120 complex mixture and the chemokine co-receptor CCR5 or/and CXCR4. An enormous effort 
has been devoted to the design and development of agents that inhibit this binding. A proof-of-concept 
that verifies the success of this strategy is Maraviroc (29, UK-427 857, Selcentry®), which is one of the 
two entry/fusion inhibitors clinically accepted nowadays for the HIV-1 chemotherapy (Figure 14) [13]. 
 
Maraviroc attaches to the CCR5 co-receptor in the target cell blocking the interaction with glycoprotein 
gp120 and stopping the propagation of the virus in patients. As can be deduced from above, the main 
effort in the design of inhibitors of the gp120-CCR5/CXCR4 attachment has been directed against the 
host cell chemokine co-receptor. Thus, only a few compounds targeting the co-receptor binding site in 
glycoprotein gp120 has been reported. We will focus strictly on the description of the potential inhibitors 
targeting the co-receptor binding site at gp120 described to date  
A series of antibodies (see section 3.5) or high molecular weight molecules directed against this 
target for HIV-1 inhibition have been proposed. However, they only display a modest neutralizing 
activity presumably due to the sterically restricted access to the epitope in the virus surface, which avoids 
a tight interaction. Therefore, there is a demanding interest in small-size molecules able to attach to the 
chemokine co-receptor binding domain in gp120 for the treatment of the HIV-1 infection. 
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Figure 14. Maraviroc structure. 
 
A representative compound is IC9564 (30), a betulinic acid derivative with substitution at the C-
28 position that inhibits A, B, and the most prevalent clade C HIV-1 viruses at IC50 values as low as 0.07 
µM independently of the tropism (Figure 15) [115]. The location of the substituent in 30 is fundamental 
for its anti-HIV-1 entry inhibition. It has been hypothesized that C-28 side chain attaches to a conserved 
region at the base of V3 loop inducing a non-functional gp120 conformation, which is incapable of 
interacting with the chemokine receptors. 
 
  
Figure 15. Chemokine co-receptor mimics to inhibit HIV-1 infection. 
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A different concept was widely used in recent years for the development of a new family of 
small-size compounds directed to block the chemokine co-receptor binding site in gp120, such as tyrosine 
sulfate mimetics. This strategy is based on the interaction of the co-receptor and the CD4-induce (iCD4) 
epitope in gp120 that requires at least two tyrosine-sulfate (Tys) residues in the extracellular N-terminus 
domain (Nt) of the co-receptor (generally CCR5). Differing from the polyanionic family of gp120-
inhibitors, these compounds would not establish electrostatic interactions with the target molecule despite 
the presence in their structures of sulfonyl acid groups. Several authors have focused their attention in 
developing tyrosine sulfate peptide-like mimetics to inhibit the HIV-1 entry into the host cell. Thus, 
Bewley and co-workers are pioneers in this area and they have recently identified a novel compound, 31, 
as a result of an in silico screening (Figure 15). Compound 31 attaches to CCR5 and CXCR4 type viruses 
in infected cells inducing both inhibition of HIV-1 entry in the low micromolar range and neutralization 
by sulfated antibodies that recognize the co-receptor binding site [116]. However, the neutralizing potency 
of this agent was not effective enough and the authors tried to overcome this problem by using 31 in 
combination with other CD4 mimetics. This may imply a previous CD4-gp120 attachment and the 
exposure of the co-receptor facilitating a neutralizing response. Another example was published in 2010 
by Robinson et al. [117] who designed an innovative tyrosine-sulfate peptidomimetic considering the α-
helical conformation that the Nt-CCR5 adopts when it interacts with the V3 conserved region in gp120. 
The resulting cyclic structure 32 showed moderate antiviral activity in CCR5 culture cells with no 
cytotoxicity (Figure 15). NMR and SPR studies permitted the postulation that 32 assumes a β-hairpin 
conformation mimicking the α-helical CCR5 epitope and interacts with the V3 conserved region in gp120 
with the involvement of the sulfate groups, preventing the attachment of the glycoprotein to the co-
receptor. 
 
As stated, the inhibition of HIV entry/fusion process by agents that block the interaction between 
gp120 and co-receptors is a highly interesting area. In this context, it has been suggested that additional 
co-factors besides CCR5 and CXCR4 could play an important role, such as membrane glycosphingolipids 
(GLSs) [118]. The binding of these GLSs to the gp120 protein is believed to be driven by a “stacking-
type” interaction established between a Phe residue located in the V3 domain and the hydrophobic face of 
the galactosyl ring of the glycolipid (presumably CH-π interaction). Blumenthal and co-workers 
synthesized a family of galactosylceramide derivatives for the HIV-1 treatment and found that 
compounds LAA-4 (33) and LAA-6 (34) attach to gp120 in a similar way to GLS, inhibiting the cell-to-
cell fusion and viral entry (IC50 = 10-40 µM) in the absence of any significant cytotoxicity (Figure 16) 
[119]. The heteroatom at the acetal moiety and the simple side chains seemed to be determinant in both 
efficacy and solubility, and these agents hold good prospects for further development into potential 
antiviral agents. 
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Figure 16. GLSs co-receptor mimics to inhibit HIV-1 infection. 
 
3.5. Small-size antibody compounds 
Very few neutralizing antibodies are able to afford effective protection against HIV-1 infection 
in humans due to the weakly immunogenic and antigenic nature of the envelope protein gp120 (see 
section 2.1). Numerous studies have been directed towards this concern over the past years and several 
potent and broadly monoclonal antibodies (mAbs) have been identified to neutralize various primary 
HIV-1 isolates of different clades in vitro and in simian models in vivo. However, further experiments 
showed limited potency against non-clade B viruses, which are the majority of the infections outside 
North America and Europe. In order to solve this limitation, two new neutralizing antibodies, PG9 and 
PG16, have been recently isolated from African clade-A infected individuals which exhibited anti-HIV 
activity against clade B and non-clade B-isolates in vitro (IC50 as low as 0.03 µM) [120].  
Despite the promising results obtained for therapies based in neutralizing antibodies, this 
approach suffers from limitations such as severe side effects, lack of oral bioavailability and high cost. 
Thus, alternative small-molecules that exploit the powerful properties of antibodies could address many 
of these disadvantages. Certain solutions have been proposed in this respect such as engineered antibody 
fragments and antibody-recruiting small molecules. On antibody fragments, two main types can be 
distinguished: single chain antibody fragments (scFv) and heavy chain variable domain antibodies 
(dAbs). The success of both families of compounds based on antibody fragments relies on the recognition 
and establishment of interactions with highly conserved epitopes in gp120 that are inaccessible or only 
partially accessible during virus entry for larger molecules like full-size antibodies. A representative 
single chain antibody fragment is m9, which is active against several panels of primary HIV-1 isolates 
from clades A-G in cell line-based assays [121]. It showed on average higher potency than the well-known 
antibodies and the clinically in-use agent efuvirtide. The major neutralizing activity of this compound is 
exerted after the formation of complex CD4-gp120 via probably the interaction with the binding site of 
the co-receptor CCR5 in gp120.  
An example of a heavy-chain domain antibody is the m36 molecule, the first and unique member 
of this family of compounds used against HIV-1 therapy [122]. It exhibits exceptional neutralizing activity 
against diverse HIV-1 strains in culture cells and primary isolates, with potency higher than scFv m9 
generally, but through a different mechanism of action: it is suggested that it targets a highly conserved 
epitope located close to the CD4 binding site on the gp120-CD4 complex. Despite this, its use as a 
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potential vaccine immunogen is limited by a very short half-life circulation in vivo and its sterically 
restricted epitope. 
The second evolving strategy previously mentioned to avoid the problems encountered during 
the administration of antibodies is the use of antibody-recruiting small molecules (ARM). In 2010 Spiegel 
et al. [123] presented this novel approach consisting in targeting existing antibodies in the patient and 
redirecting them to the HIV gp120 envelope glycoprotein. For this purpose, compound 35 was designed 
based in the well-known entry inhibitor BMS-378806 (14) that attaches to the CD4 binding site in 
glycoprotein gp120 (see section 3.3) (Figure 17). They found that 35 had the ability of both binding to 
gp120 alone blocking the interaction with CD4 and binding to high-populated anti-dinitrophenyl (anti-
DNP) antibodies along with protein gp120, forming a ternary complex which increases their visibility to 
the human immune system. Consequently, a neutralizing enhance response was produced killing either 
the free virus or infected cells. Compound 35 demonstrated anti-HIV activity in the micromolar range in 
ELISA assays and human MT-2 cell cultures and no remarkable cytotoxicity. Therefore, the great 
potential of this strategy for an effective HIV-1 treatment was proven. 
 
 
Figure 17. Small-size antibody compounds for the HIV-1 therapy. 
 
3.6. Miscellaneous 
This report has so far provided an overview of the different stages where HIV-1 inhibition can 
occur during the multi-step entry process by direct binding of the candidate agent to any of the therapeutic 
targets located in the glycoprotein gp120. However, the inhibition could occur also in an indirect fashion 
by blocking a molecular target not located in gp120 but ultimately involved in the proper function of the 
glycoprotein, whose eventual inhibition precludes the HIV-1 entry process. This “indirect inhibition” 
gained much attention with the discovery of cyclotriazadisulfonamide (CADA, 36) and analogues in the 
early 2000s, compounds directed to modulate the cellular biosynthesis of CD4 (Figure 18) [124]. This 
family of inhibitors exhibit broad antiviral activity in the micromolar range in a variety of HIV-1 clinical 
isolates at no cytotoxic levels. It is believed that these compounds do not directly attach to CD4 but they 
specifically decrease the CD4 receptor amounts in the surface of lymphocytes without altering the 
expression of other cellular receptors. Therefore, the inhibition potency shown by 36 and its derivatives 
would be directly dependent on the down-regulation expression of the CD4 receptor, thus depriving 
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gp120 of its primary receptor at the host cell. Moreover, CADA, formulated as a microbicide gel, 
demonstrated the preservation of its potency as anti-HIV inhibitor and further studies in non-human 
primates have been proposed [125].  
 
 
Figure 18. CADA derivatives as HIV-1 inhibitors. 
 
A different family of “indirect inhibitors” of the HIV-1 entry involving gp120 glycoprotein are 
the oxidoreductases. These enzymes are located in the cellular surface and are responsible of the 
formation, reduction and oxidation of disulfide bonds. It has been hypothesized that the HIV-1 
entry/fusion process is associated with the reduction of one or more disulfide(s) bond(s) in gp120 that 
induces conformational changes facilitating the unmasking of the gp41 fusion peptide [126]. Thus, agents 
that prevent the reduction of these bonds in gp120 would inhibit HIV-1 entry through this novel 
mechanism in an indirect fashion. There have been three main oxidoreductases described: protein 
disulfide isomerase (PDI), thioredoxin-1 (Trx1) or glutaredoxin-1. The enzyme that has received the most 
attention is PDI. Thus, several small-size agents have been described as PDI inhibitors. Among them, 
Bacitracin (37), the very first agent identified as a PDI inhibitor, and 5,5'-dithiobis-2-nitrobenzoic acid 
(DTNB, 38) are still of interest nowadays due to their great potential to inhibit HIV-1 (Figure 19) [127]. 
Besides the attachment to the PDI enzyme to avoid the propagation of the virus from cell-to-cell in 
CXCR4 tropic cells (in the milimolar range), the interaction of both compounds to the CD4 receptor was 
also observed. Moreover, 38 also acts in a late stage of the viral cycle (probably inactivating the protease 
enzyme) and formulated as a microbicide is able to give cell protection in vitro for hours. Therefore, it is 
a potential candidate to be used therapeutically in HIV-1 patients and advanced trials have to be 
performed to evaluate their toxicity and side effects. 
There are currently more novel compounds under investigation to block the reductase PDI 
function. In 2011, Osada group identified a family of Juniferdin derivatives 39 as new potential PDI 
inhibitors using high-throughput screening (Figure 18) [128]. These compounds specifically inhibit the 
PDI-catalyzed reduction function in the cell surface and block the HIV-entry in several cultured cells 
lines with IC50 values of approximately 160 nM. More importantly, Juniferdin derivatives are less 
cytotoxic than the PDI-inhibitors described to date, confirming that further in vivo studies should be 
performed to assess their potential clinical development. 
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More efforts have been devoted to find inhibitors of thioredoxin-1 (Trx1), which is the enzyme 
with the strongest reducing activity of the three oxidoreductases located extracellularly. A recent study 
made by Reiser at al. [129] has to be highlighted. In this work, a novel indirect strategy was used to find a 
Trx1 inhibitor based on targeting the redox system that supplies electrons to the enzyme and drives 
forward the redox process. Thus, an organo-gold compound, Auranofin (40), was demonstrated to 
efficiently decrease viral loads and increase T-cell counts in patients by the inhibition of the reduction of 
gp120. Unfortunately, this effect is carried out by 40 close to its cytotoxic concentrations (Figure 18). It 
was postulated that inhibition of thioredoxin reductase (the electron donor of Trx1 and PDI), could 
restrict the reducing activity of both enzymes. Additionally, it has been also established that some CBPs, 
previously shown to bind to carbohydrates of gp120 (see section 3.2.1), inhibit the action of Trx1 and 
PDI, presumably by sterically hindering the access of the enzymes to the virus surface. However, high 
quantities of the compounds were required and low activities were observed. 
 
 
Figure 19. HIV-1 inhibitors that block the oxidoreductase activity in the gp120 surface. 
 
As outlined above, the redox regulation of the gp120 glycoprotein could be an important indirect 
strategy for anti-HIV therapy and nowadays, the development of novel compounds that specifically 
interfere in the reduction of gp120 disulfides is of great interest.  
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4. Conclusions 
The fight against AIDS is entering a decisive period. While the development of an effective 
vaccine remains still far away, the treatment of the disease has been entrusted to the currently available 
chemotherapeutic arsenal. Barely 30 years after the discovery of HIV as the etiological cause of AIDS, 
the disease has been converted into a chronic controlled infection. Despite this major achievement, we 
have to display nevertheless only a moderate optimism, because while HAART regiments have decisively 
contributed to control the development of the HIV infection until suppression of pathological expressions 
of AIDS, drug resistances, toxicities and side-effects are still important drawbacks that compromise a 
definitive effective treatment. Moreover, latent long-term reservoirs of the pathogen are a major hurdle 
for the complete suppression of HIV from the organism.  
For the reasons depicted above, the discovery and development of novel chemotherapeutics 
directed against new targets in the HIV replicative cycle are still required for the treatment of HIV 
infection. These novel drugs should be used in combination with conventional retrovirals in HAART in 
order to inhibit HIV at as many levels as possible and minimize the risk of resistances. In this context, 
HIV entry was put in the spotlight as a critical process susceptible of effective inhibition. Viral entry 
inhibition additionally has the advantage of blocking the progress of the infection at the early steps, 
preserving an uninfected population of target cells. 
Glycoprotein gp120 is one of the molecular structures involved in the viral machinery leading 
entry of HIV into the host cell, playing a preeminent role in the mediation of CD4 receptor attachment as 
well as co-receptor binding, triggering the complex process that eventually delivers the viral material 
inside the host cell. This protein has emerged as a promising target for the development of HIV inhibitors 
as the knowledge on its role in the entry process as well as detailed structural and intimate mechanistic 
information have increased. As can be concluded from this overview, gp120 offers a wide set of different 
possibilities to interfere with its normal function. From unspecific electrostatic interactions established 
between negatively charged molecules (polyanions) and positively charged domains of the protein, to 
selective binding to sugar residues of the gp120 glycans (CBAs), both precluding efficient attachment, 
passing through protein-protein interaction inhibition such as CD4 or co-receptor binding, every family of 
gp120 inhibitors has a unique profile from the structural and mechanistic point of view. The great 
therapeutic relevance of gp120 inhibition has encouraged the search for molecular structures endowed 
with a higher inhibitory potency and selectivity towards this protein, producing a heterogeneous array of 
drugs that act at multiple points of the gp120 structure and are contributing positively to the increase of 
the potential therapeutic arsenal against HIV. Moreover, some strategies described, such as the CBA 
approach, have a great conceptual originality.  
Although there is no gp120 inhibitors clinically approved to date, many drug candidates have 
exhibited remarkable activities and some of them have been evaluated in preclinical or clinical trials with 
promising profiles to be used in the HIV-1 therapy. Additionally, gp120 inhibitors could also prevent 
viral transmission, opening a promising window to their use as microbicides. Definitively, gp120 is a 
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challenging target for HIV chemotherapy. Due to their great potential and novelty, research on drugs 
directed to inhibit gp120 should be emphasized and exploited in the future. Glycoprotein gp120 is thus at 
the forefront of strategies to treat and prevent HIV infection. 
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